NAII Q1 Sales Fall 25%, Covenant Breached; $10M Debt Now Current
NAII is trading near its 52-week low of $0.93 (3.9% above the low).
Summary
NAII's fiscal Q1 sales fell 25% to $28.1M with a $2.48M net loss, and the company confirmed a covenant breach that pushes $10.0M of debt into current liabilities against $6.7M of cash.
Key Events · Earnings and Guidance · NAII
-
Q1 Sales Drop 25%
Net sales fell to $28.1M from $37.7M, with private-label contract manufacturing down 29% to $25.6M, partly offset by a 54% rise in patent and trademark licensing revenue to $2.56M.
-
Gross Margin Collapses to 4.5%
Gross profit fell 71% to $1.27M from $4.40M as lower volumes cut factory utilization; net loss widened to $2.48M (-$0.41/share) from $0.29M (-$0.05/share).
-
Covenant Breach Confirmed
The fixed charge coverage ratio covenant was breached as of September 30, 2026, reclassifying $10.0M of term debt to current; total current liabilities are $39.6M against $6.7M of cash.
-
Forbearance Not Yet Secured
Management is negotiating a forbearance letter, waiver, or amendment with Legacy Corporate Lending and does not expect to be in compliance during fiscal 2027; the lender has not indicated it will terminate the facility.
Analysis · NAII · Life Sciences
The quarter deteriorated sharply: sales fell 25% to $28.1M and gross margin compressed to 4.5%, driving a $2.48M net loss versus $0.29M a year ago. More importantly, the company confirmed it breached the fixed charge coverage ratio on its Legacy credit facility as of September 30, 2026, forcing $10.0M of term debt into current liabilities against just $6.7M of cash — and management says it does not expect to regain compliance during fiscal 2027. A going-concern warning remains in place, with the hoped-for remedies being a headquarters sale, cost cuts, and a strategic alternatives review that includes a possible sale of the company. The lender has not yet signaled it will pull the facility, but there is no forbearance or waiver in hand.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NAII was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $0.93 to $4.96. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.